PERSONAL DATA
 |
Name:
Alvaro Galiano Ramos
DNI:
50.262.039
R
Address: General Diaz Porlier, 86.-
Madrid 28006)
Tel:+34 91 631.60.26 ; 606
355 122
e-mail:
agaliano@iqb.es
Birth
date: 12/07/1943 |
ACADEMIC DATA
Bachilleratos Español y Francés
completos
Madrid 1961-1065. Licenciatura en
Ciencias Químicas (Sección Bioquímica y Química
Médica). Universidad
Complutense. Madrid
Madrid 1995-1996. Master in Multimedia
Technology. Facultad de Bellas Artes. Universidad Complutense. Madrid
Ph.D: Faculty of Medicine. Universidad de Córdoba. Argentina
OTHER COURSES
- Barcelona 1971: Diseño
de Fármacos (Drug Design)
- Madrid 1981: Bioestatistics
Workshop (IBM)
- Basilea 1982: Good Clinical Practices
(IPHAR Workshop)
- Madrid 1982: Screening
de Fármacos (Facultad de Veterinaria)
- Barcelona 1983: CAS-On line workshop
(Facultad de C. Quimicas)
- Madrid 1984: Excerpta Medica workshop
(ICYD)
- Pamplona 1987: Good Laboratory Practices
(Universidad de Navarra)
- Amsterdam 1990: Computer Assisted
New Drug Application (Center for Professional Advancement)
- Madrid, 1992 Master in Biotechnology
(primer curso)
- Informatics: Word processing (WP),
databases (Scimate, Pro-cite, etc), Graphics (Coreldraw, Harvard Graphics),
Molecular design (Hyperchem), Medline, statistics, etc. Large experience
in INTERNET navigation and writting of HTML documents.
- Madrid, 1997. Workshop
on Menopause
- Madrid, 1997. Workshop
on Surgical Techniques in Periodontics
- Madrid, 1997. Course of 3D-animation
(Softimage)
- Barcelona, 1999: Intensive course
of theoric aspects of peripheric system nervous blockage
- Madrid, 2015: One year course on Ericksonian Hypnosis
LANGUAGES
Good level in spoken and written French
and English
Italian at conversation level
Some knowledge of technical and medical
german
PROFESSIONAL EXPERIENCE
- 1970-1975: Technical Director of
Laboratorios IQUINOSA (including the areas of production, quality control
and research)
- 1972-1973: Stage on the behalf of Iquinosa
in The Institute for Arteriosclerosis Research (Culver City, California)
owned by Dr. Lester M. Morrison
- 1975-1979: Consultant of a large
number of small and medium-sized spanish pharmaceutical laboratories.
- 1975: Cortobenzolona: registration of a new corticoid derivative (Tuplix)
- 1979-1993: Co-founder, with Laboratorios
Berenguer Beneyto, SA y Laboratorios Españoles de Farmacologia
Aplicada, del Instituto de Investigación y Desarrollo Químico-Biológico
(IQB); General Manager and Technical Manager since its foundation in 1979.
- 1984: Patent of Oxodipine a new
calcium channel blocker (the first once-a-day dihydropyridine)
- 1985: Joint-venture with DELAGRANGE
for the development of Oxodipine
- 1986: Oxodipine Project is included
in the EUREKA program (EU-59)
- 1987: Patent of Elgodipine a new
coronary vasodilator.
- 1987: Agreement between IQB and
Delagrange for cooperation in the context of Plan de Fomento.
- 1989: Manager of the international
project of development of Elgodipine, stopped in phase III (Expected
registration, 1999). Elgodipine project was included in the EUREKA
program (EU-425)
- 1993: Rupture of the IQB-DELAGRANGE
relationships.
- 1994: Elgodipine is licenced to
Prodesfarma-Almirall GROUP
- 1994: Development of ENE-ON LINE,
the first spanish provider of medical WEBs- Technical Director of ENE-ON LINE
- 1995: Development of the Spanish
Oncologic WEB of BSK (first spanish medical WEB)
- 1998-2000: Project manager of IQB-9302, a new local anesthetic, sponsored by INIBSA
- 2000-2001:
Development of the WEB-site "Resistencia Insulínica" for Glaxo Smith Kline-Beecham
- 2012-2016: Development of Dermophyton, new patented cosmeceutic useful for the treatment of recalcitrant pruritus in renal patients under hemodialysis
- February 2020: Webinar con Covid-1: ¿que sabemos sobre el Covid-19
- October 2020: Expert consultant of the company IDRE-med (London / Munich)
PUBLICATIONS
- Aerosoles basados en agua. Quimica
e Industria, 18: 6-14 (1971)
- Comparison of the cardiac effects
of IQB-M-81(*) and lignocaine. Br.J.Pharmacol., 77: 465P (1982)
- Farmacocinética de la N-acetil-homocisteina.
I. Niveles plasmáticos después de la administración
oral en la rata. Ciencia e Industria Farmaceútica, 2: 45-47
(1983)
- Asma broquial y Reproterol. Geriatrics,
5: 41-48 (1985)
- Situación actual en el tratamiento
de las Hepatopatias. En Aspectos Bioquimicos y Farmacológicos en
disfunciones hepáticas.Ed. Consejo Superior de Investigaciones
Cientificas, Madrid, 1987 pags 59-84
- Cadórniga, R., Barcia, E.,
Molina, I.T., Galiano, A.,Gutierrez, J.A. Estudio Farmacocinético
de la Guanil-cisteina. Rev.Farmacol.Clin.Exp.(1987) 4(4): 325-331
- Galiano, A. Oxodipine. Drugs of
the Future (1987) 12(7): 633-635
- Moratalla, R., Romera, R., Galiano,
A. Pharmacological Study of the New Mucolytic Drug N-Guanyl-cysteine.
Arzneim.-Forsch./Drug Res.(1986) 36 (I), 6: 918-923.
- Nyska, A., Waner, T., Pirak, M.,
Galiano, A., Zlotogorski, A. Gingival hyperplasia in rats induced by oxodipine,
a calcium channel blocker. J.Periodontol.Res.(1990) 25: 65-68
- Nyska, A., Waner, T., Zlotogorski,
A., Pirak, M., Scolnik, M., Nyska, M., Galiano, A. Oxodipine-induced gingival
hyperplasia in beagle dogs. American Journal of Pathology (1990)
137(3): 737-739
- Waner, T., Nyska, A., Nyska, M.,
Pirak, M., Sela, M., Galiano, A. Gingival Hyperplasia in Dogs Induced
by Oxodipine a calcium channel blocking agent. Toxicologic Pathology
(1988) 16 (3): 327-332.
- Waner, T., Nyska, A., Galiano, A.
Drug-induced decrease of serum-alanine and aspartate amino tranferase
in the rat. J.Clin.Chem. (1990) 28, 25-30
- Nyska, A., Waner, T., Shapira, S.,
Skutelski, E., Galiano, A., Dayan, D. Thickening of the adrenal zona glomerulosa
in dogs induced by oxodipine, a calcium channel blocker. Toxicologic
Pathology, (1992) 20 (4): 549-555
- Montastruc, P., Montastruc, Dubreuil,
J., Galiano, A. Effect of Oxodipine, a new calcium entry blocker in acute
neurogenic hypertension in dogs. Archives Internationales de Pharmacodynamie
et Thérapie, 321, 57-62 (1993)
- Acharya, D.U., Senior, R., Basu,
S., Harrison, F., Galiano A. Lahiri, A : Anti-ischemic and hemodynamic
effects of Elgodipine, a potent new generation calcium antagonist, in
chronic stable angina" European Heart Journal, 15, 665-671 (1994)
- Harrison J.J., Hierler, F., Scherer,
J., Wulsh, A, Galiano, A., Hornauer, M., Kelly, J.: Study of Pharmacokinetics
of pharmacodynamics of two preparations of Metoclopramide. Arzneim-Forsch,
44 (4): 519-521 (1994)
- Mironneau, J., Lepretre, N., Arnaudeau,
S., Rakoroarisoa, L., Galiano, A. Electrophysiological and radioligand
binding studies of Elgodipine and derivatives in portal vein myocytes.
Journal of Pharmacology and Experimental Therapeutics, 271 (3): 1209-1215.
(1994)
- Platonoff, N., Millart, H., Leperre,
A., Galiano A., Kantelip, J.P. Comparative effects of Oxodipine and Nifedipine
on contractility and intracellular pH and calcium concentration in cultured
newborn rat cardiac cells. Archives Internationales de Pharmacodynamie
et Thérapie (to be published)
- Rakotoarisoa, L., Mironneau, J.,
Galiano, A., Mironneau, C: Effects of Oxodipine and Elgodipine on (+)-3H-isradipine
binding and vascular membranes: cardiovascular selectivity. Fundamental
and Clinical Pharmacology , 8 : 546-552 (1994)
- Galiano, A., de la Motte, S., Hornauer,
M., Kelly, J., Harrison F. A preliminary investigation of the pharmacodynamics,
pharmacokinetics and renal excretion of different oral doses of elgodipine
in normal subjects. (To be published)
- Galiano, A: Elgodipine. Drugs
of the Future 20 (3) 231-234(1995)
- A Ruiz-Nuño, J.M.Hernández-Guijo,
A.Galiano, A.G.García, L. Gandía. Blockade of neuronal voltage-dependent
Na+ channels by a novel local anaesthetic. To be published
- Gomez De Segura IA, Vazquez Moreno-Planas I, Benito J, Galiano A, De Miguel E.
Electrophysiologic cardiac effects of the new local anesthetic IQB-9302 and of bupivacaine in the anesthetised dog. Acta Anaesthesiol Scand . 2002 Jul;46(6):666-73.
- Gálvez-Múgica MA, Santos-Ampuero MA, Novalbos J, Gallego Sandín S, Galiano A, Gilsanz F, García AG, Abad-Santos F.
Ulnar nerve block induced by the new local anesthetic IQB-9302 in healthy volunteers: a comparison with bupivacaine. Anesth Analg. 2001 Nov;93(5):1316-20.
- A Galiano: Estudios de toxicidad. En "El Ensayo Clínico en España" Una publicación
de Farmaindustria. (Julio 2001)
- Kalitukha Liudmila1*, Galiano Alvaro2, Harrison Francisco: Medicinal potential of the insoluble extracted fibres isolated from the Fomes fomentarius fruiting bodies. A review.
MULTIMEDIA CD-ROMS and WORKSHOPS
BOOKS
1995: Drug Treatment of hepatic diseases
2000: Toxicological Studies in NDA. Universidad Menéndez Pelayo
(Santander, Spain): A chapter of the book "Clinical Studies" Ed.Farmaindutria.
2011: Aerosoles anticolinérgicos: In Inhaloterapia. Ed. William Cristancho.
2015: "El escapelo de Oro" Biography of the french surgeon Ambroise Paré. Amazon Books. 2019.
2019: El enigma de la memoria del agua. Amazon Books
MEDICAL WEBS
1995: Oncology (Beecham
Smith-Kline)
1998: Pensa Médica
1999: GESIDA
1999: Antibióticos Pharma
2000-2001:
Resistencia Insulinica (Glaxo Smith-Kline)
2000-2017: Medciclopedia (www.iqb.es)
2011: www.pruritus.es
2022: www.iqb.es reached >330 million of unique visitors
PATENTS
Spanish Patent 443457 (Dic. 1975) Procedimiento perfeccionado para la obtención la 21-hidroxibenzoil-triamcinolona (Cortobenzolona)
Spanish Patent 467362 (sep.1978) Procedimiento de obtención de antibióticos alfa-amino-fenilacetamido beta-lactámicos n-alquil sustituidos
Spanish Patent 332.004.9 enlarged
to Germany, Austria, Belgium, Canada, France, United Kingdom, The Netherlands,
Italy, Japan y Sweden (Pincainide, local anesthetic-antiarrhythmic)
Spanish Patents 531.033 and 536.537
World-wide enlarged (Oxodipine)
European Patent 87 004 193.6 (New
Imizadol antifungal derivatives)
European Patent 87 401 799.9 (Elgodipine)
European Patent EP0500426A1 2,6-Dimethyl-4-(4'-hydroxy-3',5'-di-t-butylphenyl)-1,4-dihydropyridine derivatives, process for their preparation and their use as free radical scavengers.
Spanish Patent P-9200051 (New hydrazones
with antiproliferative activity - Tyrosine Kinase inhibitors)
Spanish Patent P-9302303 (New local
anesthetics) world-wide enlarged as PCT ES94/00107
Spanish Patent P201201001 (2015): Esential oils
and terpenes as moduladors of Transient Potential Receptors
Spanish patent P20220095 (2022) New chemical Protacs with antibiotic activity.(Pending)
COMMUNICATIONS TO CONGRESSES
Torremolinos, 1980: Synthesis and
analgesic activity of new azabicyclospirohydantoins N- substituted.
VII International Symposium on Medicinal Chemistry
Toulouse 1981: Estudio Farmacológico
del IQB-872, un nuevo mucolitico. VI Reunión Nacional de la Asociación
de Farmacológos
Salamanca 1982: Farmacocinética
de la Guanil-cisteina en la rata y el conejo. VII reunión Nacional
de la Asociación de Farmacológos
Salamanca 1982: Farmacocinética
del Sarmecillinam, un nuevo antibiótico beta-lactámico.
VII reunión Nacional de la Asociación de Farmacólogos
Salamanca 1982: Farmacolog¡a
del IQB-M-81, un nuevo anestésico local. VII Reunión Nacional
de la Asociación de Farmacólogos.
Budapest, 1984: Mise au point de
méthodes de dosage de nouvelles 2,5-benzoxazocines substituées
dans le plasma. Applications pharmacocinétiques: traitement sur
ordinateur des Resultats. International Congress of Pharmaceutical Sciences
Uppsala, 1984: New 1,4-dihydropyridines
as calcium antagonists and antihypertensive agents. VIII International
Symposium of Medicinal Chemistry
Salamanca 1984: Absorción
digestiva de Guanil-ciste¡na. IX Reunión Nacional de la
Asociación de Farmacólogos.
Fribourg, 1987: In vitro dissolution
studies of oxodipine and pharmacokinetics in laboratory animals. III
International Congress of Pharmacokinetics and Biopharmacy
Bilbao, 1987: Efectos de la oxodipina
en ratas hipertensas. XII Reunión Nacional de la Asociación
de Farmacólogos
Montpellier, 1987: Oxodipine, a
new antihypertensive agent; study between effect and pharmacokinetic
model applied to humans. 3émes Journées Méditerranéennes
de Pharmacocinétique
Montpellier, 1987: Etude de la relation
entre effet et modéle pharmacocinétique appliquée
chez l'homme par un nouvel antihypertensif: l'oxodipine. 3émes
Journées Méditerranéennes de Pharmacocinétique
Basel, 1988: Pharmacological studies
of the antihypertensive effect of oxodipine. 1st International Symposium
of Calcium Antagonists
Basel, 1988: Oxodipine, a new antihypertensive
dihydropyridine: pharmacokinetic and pharmacodynamic relationships in
man. 1st International Symposium of Calcium Antagonists
Basel, 1988: Oxodipine, a new antihypertensive
dihydropyridine: pharmacokinetics after repeated oral doses in relation
to the effect.1st International Symposium of Calcium Antagonists
Basel, 1988: Cardiac electrophysiological
effects of Oxodipine in the unanestatized dog. Comparison with nifedipine.
1st International Symposium of Calcium Antagonists
Basel, 1988: Determination of Clinical
Tolerance of 20 mg daily doses of oxodipine (IQB-837) in six male volunteers
during a period of 8 days. 1st International Symposium of Calcium Antagonists
Munich 1988: Recovery from gingival
hyperplasia induced by oxodipine, a calcium channel blocker. III International
Congress on Toxicology
Murcia 1988: Nuevas 1,4-dihidropiridinas
como antagonistas del calcio. XIII Reunión Nacional de la Asociación
de Farmacólogos.
Bilbao 1988: Efecto hemodinámico
de dos nuevas dihidropiridinas, IQB-872D e IQB-875D en el perro anestesiado.
XXI Congreso Nacional de Cardiolog¡a
Eilat, 1989: Common side effects
on calcium antagonists in laboratory animals. 2nd International Conference
on Calcium Antagonists
Tokyo, 1989: The antithrombotic,
thrombolytic and vasoprotective effect of Oxodipine, a new calcium antagonist.
12th Int.Cong.Throm.Haemost.
Badajoz, 1989: Estudio hemodinámico
de la elgodipina en rata, perro y cerdo. XIV Reunión Nacional
de la Asociación de Farmacólogos
Amsterdam, 1990: Effects of elgodipine
in vascular smooth muscles. 11st Int.Congres Pharmacology
Amsterdam, 1990: Elgodipine vs.
nicardipine: hemodynamic changes in anesthetized dogs. 11st Int.Congress
Pharmacol.
Amsterdam, 1990: Study of the agonism
and antagonism of elgodipine on different types of receptors. 11st Int.Congress
Pharmacol.
Basel, 1991: Antihypertensive activity
of oxodipine, a new dihydropyridine calcium blocker. Tolerance and dose-effect
relationship determination. 5th Int.Symp.Calcium Antagonists.
Benalmádena (Málaga)
(1992): Valoración de captadores de radicales libres mediante
el modelo de cardiotoxicidad. Rev.farm.clin.exp. 1992 Número especial
Montreal (1994): Pharmacology of
a new potent local anesthetic. 15th Int.Congress Pharmacol.
Amsterdam, 1994. Anti-ischemic and
Haemodynamic Effects of elgodipine: a new calcium antagonist. Int. Congress Cardiology,
Paris (1995). Pharmacokinetics and
pharmacodynamics of different oral doses of Elgodipine in normal subjects.
1st Congress of the European Association for Clinical Pharmacology and
Therapeutics. Abst 470
Lisboa
(2000): Blockage of neuronal, voltage-dependent Na-Channels by the Novel
Local Anesthetic, IQB-9302 (Abst 09-010)
|
